Live Webinar - The Future of Life Sciences VC: Examining Specialist vs. Hyper-Targeted Investment Strategies
Want to hear how life sciences VCs are navigating evolving market conditions? Our partner Farzad will lead a debate about the effectiveness of specialist funds versus hyper-targeted approaches, offering valuable perspectives on shaping successful investment strategies. Thursday May 8 16:00-17:00 CEST
In an evolving biotech and medtech investment landscape, life sciences VCs are adopting increasingly distinct approaches. Some embrace a specialist model, investing across a broad range of technologies and therapeutic areas. Others double down with hyper-targeted strategies, focusing on a narrow field to build deep expertise and insight.
But which path is more effective for driving returns, de-risking investments, and enabling impactful innovation?
Join us for this dynamic expert panel debate as we explore the models shaping the next generation of life science venture capital.
You will hear from Willem van Werperen – Pluvia Biotech, Ester Caffarel-Salvador – Chiesi, Bauke Anninga – M Ventures, Jonathan Gertler – Back Bay Life Science Advisors, Morgan Haller – Forbion.
More info and registration here.